ELDN earnings analysis
What we found in ELDN's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Eledon reported a Q2 2026 diluted EPS loss of $0.27, while revenue, gross margin, operating margin, and free cash flow were not disclosed in the provided filing text. Clinical development progressed, including a roughly 600-patient Phase 3 kidney-transplant trial targeted for late 2026 and insulin independence in all 12 reported islet-transplant patients. However, the financial outlook is materially pressured: the six-month net loss was $70.7 million, liquidity was $88.8 million, and management concluded that substantial doubt exists about the company’s ability to continue as a going concern without additional financing.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Controls remained effective
- Management concluded that disclosure controls and procedures were effective at the reasonable-assurance level as of June 30, 2026, and reported no changes in internal control over financial reporting that materially affected, or were reasonably likely to materially affect, controls during the quarter.
- Late-stage clinical programs advanced
- Clinical progress remained positive: 100% of the 12 islet-transplant patients achieved insulin independence, while FDA alignment supports a roughly 600-patient Phase 3 kidney-transplant trial.
- Kidney Phase 3 targeted for late 2026
- Management reported that the planned Phase 3 kidney-transplant trial remains on track to initiate in late 2026, subject to securing the substantial additional capital required for the trial.
- No material litigation disclosed
- The company reported no material legal proceedings, stating that neither it nor its subsidiaries is a party to any material legal proceeding as of the filing.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Going-concern and financing risk
- The company disclosed substantial doubt about its ability to continue as a going concern: as of June 30, 2026, cash, cash equivalents and short-term investments were $88.8 million, and management said it did not have sufficient cash to fund operations for at least 12 months from issuance of the financial statements.
- Persistent losses and no product revenue
- The six-month net loss was $70.7 million and the accumulated deficit was $471.9 million as of June 30, 2026. The company has generated no revenue from product sales and expects losses to continue for several years.
- Large potential equity dilution
- The company had 80,891,404 common shares outstanding and pre-funded and common warrants exercisable for 48,693,790 shares as of June 30, 2026, creating substantial potential dilution and possible downward pressure on the stock price.
- Trial funding may be unavailable
- Initiating the Phase 3 kidney-transplant trial and a potential company-sponsored islet-cell study would require substantial additional capital; management stated that financing may not be available on acceptable terms or at all.
- Manufacturing and tariff exposure
- The company relies on third parties for manufacturing and has no arrangements for redundant supply. Its suppliers could also face higher costs from proposed pharmaceutical tariffs, including a proposed 100% tariff on branded and patented pharmaceutical products.
- Product-liability coverage may be inadequate
- The company disclosed that it currently carries $10.0 million of aggregate product-liability insurance with a $10.0 million per-incident limit, which may be inadequate as clinical programs expand.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.27
What they said about what is next.
No numeric revenue or EPS guidance was provided. Management stated that cash, cash equivalents and short-term investments of $88.8 million are expected to fund operations into the second quarter of 2027, and that the planned Phase 3 kidney-transplant trial remains on track to initiate in late 2026.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 13, 2026
- Eledon Pharmaceuticals reported a significant net loss of $39.0 million for Q1 2026, escalating from a loss of $6.5 million in Q1 2025. Operating expenses rose to $21.2 million, primarily due to increased research and…
- 10-K · March 19, 2026
- Eledon positions itself as a focused immunology biotech advancing tegoprubart (anti-CD40L) for prevention of allograft rejection in kidney transplantation and for ALS (ALS development paused absent financing). The 10-K…
- 10-Q · November 14, 2025
- Eledon reported a net loss for Q3 2025 of $(17,459) thousand (basic EPS -$0.21) vs net income $76,971 thousand (EPS $1.05) in the prior-year quarter, driven largely by a much smaller change in fair value of warrant…
- 10-Q · November 12, 2024
- Eledon reported a Q3 net income of $76.971 million driven by a $96.439 million non‑cash gain on warrant liabilities; excluding that gain the quarter would have been a loss of $19.468 million. Operating expenses rose…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ELDN makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever